% | $
Quotes you view appear here for quick access.


  • merlin1990 Jan 9, 2013 12:10 PM Flag

    Sanofi-Genzyme acquisition, what's the likelihood?

    They have the CEO of Genzyme now on board. As you know, Sanofi-Genzyme focuses on rare disease that is why I think that Krystexxa would be something they will be interested on. There are other drugs out there for gout, but Krsytexxa is the only one that address those patients that were not responsive to other gout treatments.

    "Cambridge, Mass. and Carlsbad, Calif., Dec. 14, 2012 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for its marketing authorization application (MAA) for KYNAMRO TM (mipomersen) for the treatment of patients with Homozygous Familial Hypercholesterolaemia (HoFH). Genzyme plans to request a re-examination of the CHMP Opinion."
    -- somehow this makes me think that this failure might be a good thing for Savient. This makes krystexxa very appealing...

    SortNewest  |  Oldest  |  Most Replied Expand all replies